These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33740872)

  • 1. Preclinical Optimization and Safety Studies of a New Lentiviral Gene Therapy for p47
    Schejtman A; Vetharoy W; Choi U; Rivat C; Theobald N; Piras G; Leon-Rico D; Buckland K; Armenteros-Monterroso E; Benedetti S; Ashworth MT; Rothe M; Schambach A; Gaspar HB; Kang EM; Malech HL; Thrasher AJ; Santilli G
    Hum Gene Ther; 2021 Sep; 32(17-18):949-958. PubMed ID: 33740872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lentiviral gene therapy rescues p47
    Schejtman A; Aragão-Filho WC; Clare S; Zinicola M; Weisser M; Burns SO; Booth C; Gaspar HB; Thomas DC; Condino-Neto A; Thrasher AJ; Santilli G
    Gene Ther; 2020 Sep; 27(9):459-469. PubMed ID: 32533104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous Disease.
    Brendel C; Rothe M; Santilli G; Charrier S; Stein S; Kunkel H; Abriss D; Müller-Kuller U; Gaspar B; Modlich U; Galy A; Schambach A; Thrasher AJ; Grez M
    Hum Gene Ther Clin Dev; 2018 Jun; 29(2):69-79. PubMed ID: 29664709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic Granulomatous Disease: a Comprehensive Review.
    Yu HH; Yang YH; Chiang BL
    Clin Rev Allergy Immunol; 2021 Oct; 61(2):101-113. PubMed ID: 32524254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease.
    Roesler J; Brenner S; Bukovsky AA; Whiting-Theobald N; Dull T; Kelly M; Civin CI; Malech HL
    Blood; 2002 Dec; 100(13):4381-90. PubMed ID: 12393624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9-generated p47
    Wrona D; Siler U; Reichenbach J
    Sci Rep; 2017 Mar; 7():44187. PubMed ID: 28287132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.
    Santilli G; Almarza E; Brendel C; Choi U; Beilin C; Blundell MP; Haria S; Parsley KL; Kinnon C; Malech HL; Bueren JA; Grez M; Thrasher AJ
    Mol Ther; 2011 Jan; 19(1):122-32. PubMed ID: 20978475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy.
    Brendel C; Hänseler W; Wohlgensinger V; Bianchi M; Tokmak S; Chen-Wichmann L; Kuzmenko E; Cesarovic N; Nicholls F; Reichenbach J; Seger R; Grez M; Siler U
    Hum Gene Ther Methods; 2013 Jun; 24(3):151-9. PubMed ID: 23489116
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Kuhns DB; Hsu AP; Sun D; Lau K; Fink D; Griffith P; Huang DW; Priel DAL; Mendez L; Kreuzburg S; Zerbe CS; De Ravin SS; Malech HL; Holland SM; Wu X; Gallin JI
    Blood Adv; 2019 Jan; 3(2):136-147. PubMed ID: 30651282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis.
    Chiriaco M; Farinelli G; Capo V; Zonari E; Scaramuzza S; Di Matteo G; Sergi LS; Migliavacca M; Hernandez RJ; Bombelli F; Giorda E; Kajaste-Rudnitski A; Trono D; Grez M; Rossi P; Finocchi A; Naldini L; Gentner B; Aiuti A
    Mol Ther; 2014 Aug; 22(8):1472-1483. PubMed ID: 24869932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic granulomatous disease: Clinical, molecular, and therapeutic aspects.
    Chiriaco M; Salfa I; Di Matteo G; Rossi P; Finocchi A
    Pediatr Allergy Immunol; 2016 May; 27(3):242-53. PubMed ID: 26680691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lentiviral gene therapy for X-linked chronic granulomatous disease.
    Kohn DB; Booth C; Kang EM; Pai SY; Shaw KL; Santilli G; Armant M; Buckland KF; Choi U; De Ravin SS; Dorsey MJ; Kuo CY; Leon-Rico D; Rivat C; Izotova N; Gilmour K; Snell K; Dip JX; Darwish J; Morris EC; Terrazas D; Wang LD; Bauser CA; Paprotka T; Kuhns DB; Gregg J; Raymond HE; Everett JK; Honnet G; Biasco L; Newburger PE; Bushman FD; Grez M; Gaspar HB; Williams DA; Malech HL; Galy A; Thrasher AJ;
    Nat Med; 2020 Feb; 26(2):200-206. PubMed ID: 31988463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic Tumors in a Mouse Model of X-linked Chronic Granulomatous Disease after Lentiviral Vector-Mediated Gene Therapy.
    Jofra Hernández R; Calabria A; Sanvito F; De Mattia F; Farinelli G; Scala S; Visigalli I; Carriglio N; De Simone M; Vezzoli M; Cecere F; Migliavacca M; Basso-Ricci L; Omrani M; Benedicenti F; Norata R; Rancoita PMV; Di Serio C; Albertini P; Cristofori P; Naldini L; Gentner B; Montini E; Aiuti A; Mortellaro A
    Mol Ther; 2021 Jan; 29(1):86-102. PubMed ID: 33010230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease.
    Dinauer MC; Li LL; Björgvinsdóttir H; Ding C; Pech N
    Blood; 1999 Aug; 94(3):914-22. PubMed ID: 10419882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cells.
    Becker S; Wasser S; Hauses M; Hossle JP; Ott MG; Dinauer MC; Ganser A; Hoelzer D; Seger R; Grez M
    Hum Gene Ther; 1998 Jul; 9(11):1561-70. PubMed ID: 9694155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34+ peripheral blood progenitors as a target for genetic correction of the two flavocytochrome b558 defective forms of chronic granulomatous disease.
    Li F; Linton GF; Sekhsaria S; Whiting-Theobald N; Katkin JP; Gallin JI; Malech HL
    Blood; 1994 Jul; 84(1):53-8. PubMed ID: 7517218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of patients with p47-phox-deficient chronic granulomatous disease: The significance of recombination events between the p47-phox gene (NCF1) and its highly homologous pseudogenes.
    Vázquez N; Lehrnbecher T; Chen R; Christensen BL; Gallin JI; Malech H; Holland S; Zhu S; Chanock SJ
    Exp Hematol; 2001 Feb; 29(2):234-43. PubMed ID: 11166463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gene therapy for inherited diseases using heamatopoietic stem cells--gene therapy for patients with chronic granulomatous disease].
    Nunoi H; Ishibashi F
    Hum Cell; 1999 Sep; 12(3):103-8. PubMed ID: 10695016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing.
    Kaufmann KB; Brendel C; Suerth JD; Mueller-Kuller U; Chen-Wichmann L; Schwäble J; Pahujani S; Kunkel H; Schambach A; Baum C; Grez M
    Mol Ther; 2013 Mar; 21(3):648-61. PubMed ID: 23207695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of proteoliposomes on X-linked chronic granulomatous disease: proof of concept using macrophages differentiated from patient-specific induced pluripotent stem cells.
    Brault J; Vaganay G; Le Roy A; Lenormand JL; Cortes S; Stasia MJ
    Int J Nanomedicine; 2017; 12():2161-2177. PubMed ID: 28356734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.